A Double Blind Comparison of Omacor and Placebo as Secondary Prevention Against Cardiovascular Events in Patients Undergoing Chronic Hemodialysis.

Trial Profile

A Double Blind Comparison of Omacor and Placebo as Secondary Prevention Against Cardiovascular Events in Patients Undergoing Chronic Hemodialysis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2008

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Sponsors Pronova BioPharma
  • Most Recent Events

    • 12 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top